Key facts
- This page summarizes Frank Mccormick's Form 4 filing for BridgeBio Pharma, Inc. (BBIO).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Sep 2025, 18:06.
Frank Mccormick - 05 Sep 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)
- Reporting relationship
- Director
- Issuer ticker
- BBIO
- Reported as of
- 05 Sep 2025
- Net transaction value
- -$3,051,464
- SEC form
- 4
- Accepted by SEC
- 08 Sep 2025, 18:06:31 UTC
- Prior SEC filing
- 28 Aug 2025
- Next SEC filing
- 29 Oct 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Will Solis, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Frank Mccormick filed Form 4 for BridgeBio Pharma, Inc. (BBIO) on 08 Sep 2025.
Change
- Previous filing in this sequence was filed on 28 Aug 2025.
- Current net transaction value: -$3,051,464.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001257809
Primary reporting owner
MCCORMICK FRANK
- Relationship
- Director
- Address
- C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO
- Signature
- /s/ Will Solis, Attorney-in-Fact
- Signature date
- 08 Sep 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BBIO
transaction
Common Stock
Options Exercise
- Transaction value
- $882,080
- Shares
- +74,000
- Change %
- +89%
- Price
- $11.92
- Shares after
- 157,275
- Date
- 05 Sep 2025
- Ownership
- Direct
BBIO
transaction
Common Stock
Sale
- Transaction value
- $3,933,544
- Shares
- -74,000
- Change %
- -47%
- Price
- $53.16
- Shares after
- 83,275
- Date
- 05 Sep 2025
- Ownership
- Direct
- Footnotes
- F1
BBIO
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 879,979
- Date
- 05 Sep 2025
- Ownership
- By the Francis P. McCormick Rev Trust U/A DTD 1/27/2017
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BBIO
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -74,000
- Change %
- -47%
- Price
- $0.000000
- Shares after
- 84,814
- Date
- 05 Sep 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 74,000
- Exercise price
- $11.92
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the weighted average sale price of the shares sold from $52.96 to $53.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
Footnote F2
The stock option vests and becomes exercisable in three annual installments after February 21, 2023, with a final vesting date of February 21, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.
SEC remarks
Exhibit 24 - Power of Attorney